Stockreport

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years [Yahoo! Finance]

INmune Bio Inc. - Common stock  (INMB) 
PDF on developing treatments that harness the patient's innate immune system to fight disease, is pleased to share an update on two patients from the Phase 1b trial complete [Read more]